The value of low-dose intraperitoneal immunoglobulin administration in the treatment of peritoneal dialysis-related peritonitis

Journal of Nephrology

Volumn 17, Issue 3, 2004, Pages 427-430

  Coban, Erkan ^a   Ozdogan, Mustafa ^a   Tuncer, Murat ^a   Bozcuk, Hakan ^a   Ersoy, Fevzi ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

CAPD peritonitis; Intraperitoneal immunoglobulin; Peritoneal dialysis

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN G; NETILMICIN; SULTAMICILLIN;

ABDOMINAL PAIN; ADULT; AGE DISTRIBUTION; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DIALYSATE LEVEL; DRUG EFFICACY; DRUG SAFETY; EMPIRICISM; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; NEUTROPHIL; OPSONIZATION; PATHOGENESIS; PATIENT MONITORING; PERITONITIS; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TREATMENT PLANNING;

ANTI-BACTERIAL AGENTS; DIALYSIS SOLUTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PERITONEAL CAVITY; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONITIS;

EID: 4243171508     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Verbrugh HA, Keane WF, Hoidal JR, Freiberg MR, Elliott GR, Peterson PK. Peritoneal macrophages and opsonins: antibacterial defense in patients undergoing chronic peritoneal dialysis. J Infect Dis 1983; 147: 1018-29.
2. Harvey DM, Sheppard KJ, Morgan AG, Fletcher J. Neutrophil function in patients on continuous ambulatory peritoneal dialysis. Br J Haematol 1988; 68: 273-8.
3. Lewis S, Holmes C. Host defense mechanisms in the peritoneal cavity of continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1991; 11: 14-21.
4. Holmes C, Lewis S. Host defense mechanisms in the peritoneal cavity of continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1991; 11: 112-7.
5. Holmes CJ. Peritoneal host defense mechanisms in peritoneal dialysis. Kidney Int 1994; 48 (suppl): S58-70.
6. Schroeder CH, Bakkeren JA, Weemaes CM, Mormens LA. IgG2 deficiency in young children treated with continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1989; 9: 261-5.
7. Muller S, Masson V, Droesch S, Donner M, Stoltz JF. Phagocytosis and membrane fluidity: application to the evaluation of opsonizing properties of fibronectin. Biorheology 1989; 26: 323-30.
8. Brown EJ. The role of extracellular matrix proteins in the control of phagocytosis. J Leukoc Biol 1986; 39: 579-91.
9. Hormann H. Fibronectin cell interaction. Klin Wochenschr 1986; 7: 51-3.
10. Bohnsack JF, O'Shea JJ, Takahashi T, Brown EJ. Fibronectin-enhanced phagocytosis of an alternative pathway activator by human culture-derived macrophages is mediated by the C4b/C3b complement receptor (CR1). J Immunol 1985; 135: 2680-6.
11. Carozzi S, Nasini MG, Kunkl A, Cantarella S, Lamperi S. Response of CAPD patients with a high incidence of peritonitis to intraperitoneal immunoglobulin therapy. ASAIO Trans 1988; 34: 635-9.
12. Ersoy FF, Sezer T, Ozcan S, Erturk J, Gultekin M. Effectiveness of low-dose intraperitoneal human gamma globulin in the treatment of refractory CAPD peritonitis. Perit Dial Int 1996; 16: 328-9.
13. Fried L, Piraino B. Peritonitis. In Gokal R, Khanna R, Krediet R, Nolph KD Eds. Textbook of Peritoneal Dialysis. Dordrecht: Kluwer Academic 2000; 545-65.
14. Fried LF, Bernardini J, Johnston JR, Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 1996; 7: 2176-82.
15. Garcia-Lopez E, Lindholm B, Tranaeus A. Biocompatibility of new peritoneal dialysis solutions: clinical experience. Perit Dial Int 2000; 20: 48-56.
16. Ha H, Yu MR, Choi HN, Cha MK, Kang HS, Kim MH, Lee HB. Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation. Perit Dial Int 2000; 20: 10-18
17. Gordon DL, Rice JL, Avery VM. Surface phagocytosis and host defence in the peritoneal cavity during continuous ambulatory peritoneal dialysis. Eur J Clin Microbiol Infect Dis 1990; 9: 191-7.
18. Akman S, Guven AG, Ince S, Yegin O. Effect of intraperitoneal immunoglobulin infusion on neutrophil function in CAPD children with and without peritonitis. Adv Perit Dial 1998; 14: 239-42.
19. Nakayama I, Kawaguchi H, Yamaji E, Akieda Y, Itokowa K. Therapeutic effect of a new human immunoglobulin SM-4300 on the severe infections in surgical patients. Jpn J Antibiot 1985; 38: 2617-21.